- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Emerging illicit drugs pose a significant clinical challenge. This handbook offers an engaging, concise guide to managing these challenges.
Andere Kunden interessierten sich auch für
- United Nations: International Narcotics Control BoardPrecursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances 201752,99 €
- United Nations: International Narcotics Control BoardPsychotropic Substances 2017102,99 €
- Specification of Drug Substances and Products144,99 €
- Concepts of Addictive Substances and Behaviours Across Time and Place70,99 €
- United Nations: Office on Drugs and CrimeManufacture of Narcotic Drugs, Psychotropic Substances and Their Precursors40,99 €
- Christian RatschThe Encyclopedia of Psychoactive Plants102,99 €
- Mark S. JohnsonUnderstanding Risk to Wildlife from Exposures to Per- and Polyfluorinated Alkyl Substances (PFAS)138,99 €
-
-
-
Emerging illicit drugs pose a significant clinical challenge. This handbook offers an engaging, concise guide to managing these challenges.
Produktdetails
- Produktdetails
- Verlag: RCPsych/Cambridge University Press
- Seitenzahl: 142
- Erscheinungstermin: 8. Oktober 2020
- Englisch
- Abmessung: 190mm x 120mm x 9mm
- Gewicht: 162g
- ISBN-13: 9781911623090
- ISBN-10: 1911623095
- Artikelnr.: 59938920
- Verlag: RCPsych/Cambridge University Press
- Seitenzahl: 142
- Erscheinungstermin: 8. Oktober 2020
- Englisch
- Abmessung: 190mm x 120mm x 9mm
- Gewicht: 162g
- ISBN-13: 9781911623090
- ISBN-10: 1911623095
- Artikelnr.: 59938920
Owen Bowden-Jones is Consultant in Addiction Psychiatry and Founder of the CNWL Club Drug Clinic, London, and Honorary Professor at University College London. He is Chair of the Advisory Council on the Misuse of Drugs and National Clinical Adviser to the Alcohol, Drugs and Tobacco division at Public Health England.
Part I: 1. Introduction 2. What are NPS and Club Drugs and why are they important
3. A brief history of NPS production and distribution
4. Drugs classification framework for Club Drugs and NPS
5. Clinical challenge of Club Drugs and NPS
Part II. Stimulant Drugs
6. Stimulant drugs: introduction
7. Stimulant drugs: cocaine
8. Stimulant drugs: amphetamine-type
9. Stimulant drugs: methamphetamine
10. Stimulant drugs: MDMA
11. Stimulant drugs: synthetic cathinones
Part III. Depressant Drugs
12. Depressant drugs: introduction
13. Depressant drugs: GHB/GBL
14. Depressant drugs: Fentanyl, Fentanyl analogues and other opioid NPS
15. Depressant drugs: Benzodiazepine NPS
16. Depressant drugs: Ketamine and its anaologues
Part IV. Synthetic Cannabinoid Receptor Agonsits
17. Synthetic cannabinoid receptor agonists (SCRAs)
Part V. Hallucinogens
18. Hallucinogens
Part VI. Concluding Remarks and References
19. Concluding Remarks
20. References.
3. A brief history of NPS production and distribution
4. Drugs classification framework for Club Drugs and NPS
5. Clinical challenge of Club Drugs and NPS
Part II. Stimulant Drugs
6. Stimulant drugs: introduction
7. Stimulant drugs: cocaine
8. Stimulant drugs: amphetamine-type
9. Stimulant drugs: methamphetamine
10. Stimulant drugs: MDMA
11. Stimulant drugs: synthetic cathinones
Part III. Depressant Drugs
12. Depressant drugs: introduction
13. Depressant drugs: GHB/GBL
14. Depressant drugs: Fentanyl, Fentanyl analogues and other opioid NPS
15. Depressant drugs: Benzodiazepine NPS
16. Depressant drugs: Ketamine and its anaologues
Part IV. Synthetic Cannabinoid Receptor Agonsits
17. Synthetic cannabinoid receptor agonists (SCRAs)
Part V. Hallucinogens
18. Hallucinogens
Part VI. Concluding Remarks and References
19. Concluding Remarks
20. References.
Part I: 1. Introduction 2. What are NPS and Club Drugs and why are they important
3. A brief history of NPS production and distribution
4. Drugs classification framework for Club Drugs and NPS
5. Clinical challenge of Club Drugs and NPS
Part II. Stimulant Drugs
6. Stimulant drugs: introduction
7. Stimulant drugs: cocaine
8. Stimulant drugs: amphetamine-type
9. Stimulant drugs: methamphetamine
10. Stimulant drugs: MDMA
11. Stimulant drugs: synthetic cathinones
Part III. Depressant Drugs
12. Depressant drugs: introduction
13. Depressant drugs: GHB/GBL
14. Depressant drugs: Fentanyl, Fentanyl analogues and other opioid NPS
15. Depressant drugs: Benzodiazepine NPS
16. Depressant drugs: Ketamine and its anaologues
Part IV. Synthetic Cannabinoid Receptor Agonsits
17. Synthetic cannabinoid receptor agonists (SCRAs)
Part V. Hallucinogens
18. Hallucinogens
Part VI. Concluding Remarks and References
19. Concluding Remarks
20. References.
3. A brief history of NPS production and distribution
4. Drugs classification framework for Club Drugs and NPS
5. Clinical challenge of Club Drugs and NPS
Part II. Stimulant Drugs
6. Stimulant drugs: introduction
7. Stimulant drugs: cocaine
8. Stimulant drugs: amphetamine-type
9. Stimulant drugs: methamphetamine
10. Stimulant drugs: MDMA
11. Stimulant drugs: synthetic cathinones
Part III. Depressant Drugs
12. Depressant drugs: introduction
13. Depressant drugs: GHB/GBL
14. Depressant drugs: Fentanyl, Fentanyl analogues and other opioid NPS
15. Depressant drugs: Benzodiazepine NPS
16. Depressant drugs: Ketamine and its anaologues
Part IV. Synthetic Cannabinoid Receptor Agonsits
17. Synthetic cannabinoid receptor agonists (SCRAs)
Part V. Hallucinogens
18. Hallucinogens
Part VI. Concluding Remarks and References
19. Concluding Remarks
20. References.